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Background/aim: Autism spectrum disorder (ASD) describes a range of neurodevelopmental disabilities that impair behavior and
communication. Although it is relatively prevalent, the pathophysiology is still subject to speculation and debate. The aim of this study
is to identify a possible association between interleukin-6, -8, -9, and -10 and tumor necrosis factor alpha (TNF-α) in autism among
Jordanian children by comparing the plasma levels of these cytokines in autistic children with those of their unaffected siblings and
unrelated healthy controls.
Materials and methods: In this study, 80 Jordanian children under the age of 12 with diagnosed autism were selected. For comparison,
51 unaffected siblings and 86 unrelated healthy controls were also recruited. Venous blood was collected and interleukin levels in all
three groups were investigated.
Results: Interleukin-6 was found to be significantly higher in the plasma of both autistic children and their siblings compared with
the unrelated healthy control group (P < 0.05). As for interleukin-8 and TNF-α, plasma levels were significantly higher exclusively in
autistic children compared to their siblings and unaffected control subjects (P < 0.001, P < 0.001). There was no significant difference
between plasma levels of the previously mentioned cytokines in the siblings and the unrelated control group. As for interleukin-9 and
interleukin-10, no significant differences were found between all three groups (P = 0.15, P = 0.35).
Conclusion: We found that interleukin-8 and TNF-α were exclusively elevated in autistic Jordanian children, while interleukin-6
was elevated in both autistic children and their siblings, potentially dismissing its significance. These results may lead to a better
understanding of the disorder’s pathophysiology, early testing, and diagnosis.
Key words: Autism, interleukins, siblings, cytokines, Jordan

1. Introduction
Autism spectrum disorder (ASD) is a heterogeneous
disorder that consists of a range of neurodevelopmental
disabilities
causing
significant
behavioral
and
communicational deficits [1]. According to the Centers
for Disease Control and Prevention, about 1 in 59 children
aged 8 years old are diagnosed with ASD in the United
States with a male predisposition [2]. Studies among
Arabs and in the Middle East are few, but a recent study
in Lebanon revealed a comparable prevalence, which was
1 in 66 among toddlers 16–48 months old [3]. While there
are no official statistics about the prevalence of autism in
Jordan due to the lack of local comprehensive studies in
this field, experts affirm that there are about 8000 autistic
individuals. Although the prevalence of ASD is significant,

the etiology, which constitutes an interaction between
genetics and environment, is largely unknown.
Recently, several studies have suggested a correlation
between ASD and abnormal immune activation [4]. For
instance, there is a high incidence of autistic subjects in
families with other autoimmune disorders such as celiac
disease and rheumatoid arthritis, suggesting a potential
role for immune dysfunction in the pathophysiology of
ASD [5]. At the cellular level, studies revealed skewed and
dysfunctional immune cell populations in children with
ASD. Moreover, children with ASD have an increased
total number of peripheral blood monocytes, and their
monocytes produce significantly higher amounts of
cytokines in response to stimulation [6,7].
Cytokines are a superfamily of proteins that are an
integral part of the signaling network between cells. In
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addition to being the primary regulators of inflammation
and coordinating the response to infection and associated
immune challenges, cytokines are involved in many
physiological processes including growth, development,
and cell differentiation as well. It was previously thought
that the peripheral immune system does not cross the
blood–brain barrier (BBB), but overwhelming new
evidence suggests that it might play a role in neuronal
functions. For instance, several proinflammatory
cytokines can cross the BBB, affect the hypothalamus,
and trigger so-called sickness behavior [8]. Cytokines
can also modulate brain function, affecting cognitive
and emotional processing, and might be responsible
for the mood and sleep disturbances commonly seen
in children with ASD [9]. A number of recent studies
have demonstrated an increase in proinflammatory
cytokines and a decrease in antiinflammatory cytokine
levels in children with ASD compared with healthy
individuals [10]. Not all cytokines were associated with
ASD; among the most replicated results were higher
levels of interleukin-6 (IL-6), interleukin-8 (IL-8), and
tumor necrosis factor-α (TNF-α), and lower levels of the
antiinflammatory interleukin-10 (IL-10) [11–13]. On the
other hand, interleukin-9 (IL-9) is a proinflammatory
cytokine that modulates the development of ion channels
and action potentials in cultured brain neurons. However,
several studies revealed no association between IL-9 blood
levels and the pathophysiology of ASD.
ASD has always been regarded as a predominantly
genetic disorder. A recent twin-study metaanalysis
demonstrated a heritability estimate of 64%–91% [14].
However, other potential contributing factors in the
pathophysiology of ASD can be environmental or genetic/
environmental interactions. A previous study has shown a
slight decrease in B-cell levels in children with ASD as well
as their unaffected siblings [15], while other studies found
that both children with ASD and their unaffected siblings
have antibrain antibodies in their blood [16]. Hence,
investigating environmental and immunological factors
between children with ASD and their unaffected siblings
can reduce heterogeneity and assist in the identification
of immunological factors involved with ASD. Therefore,
the aim of this study is to investigate the plasma levels
of IL-6, IL-8, IL-9, IL-10, and TNF-α in autistic children
compared with their unaffected siblings and unrelated
healthy control children.
2. Materials and methods
2.1. Sample
A total of 96 autistic Jordanian children (81 males, 19 females) younger than 12 years old diagnosed with ASD by
experienced child psychiatrists and neuropediatricians according to the Diagnostic and Statistical Manual of Mental
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Disorders (fifth edition) were initially recruited for this
study from pediatric clinics and local special healthcare
centers, along with their siblings. After written consent
from their parents was obtained, the ASD group was interviewed by a team of child psychiatrists, as well as the
principal investigator, to obtain the medical history and
achieve a unified diagnosis. They fell within the subclass
of “Childhood Autism” according to Section F84.0 in the
10th revision of the International Statistical Classification.
Control subjects were recruited from among visitors to our
local university hospital for any reason other than acute or
chronic disease, and/or children who accompanied a family member to the hospital. This study was approved by the
research committee of the School of Medicine at our institute and the ethics committee of our institute’s hospital
(reference number 10/2018/1181), and it was carried out
in accordance with ethical standards.
Karyotyping was performed for all autistic subjects to
exclude syndromic autism and genetic abnormalities that
are associated with ASD, resulting in the exclusion of two
male subjects. Other exclusion criteria included chronic
illnesses, allergies, or symptoms of illnesses and infections
currently or in the last 3 months and a restricted diet or
supplementation regimen. As a result, a total of 16 subjects (14 males and 13 females) were excluded. Fifty-one
siblings of the autistic children and 86 unrelated healthy
controls (UHCs) who did not have a family history of autism were matched for sex and age and assigned as the sibling and UHC groups, respectively. Descriptive data can be
found in the Table.
2.2. Blood collection and interleukin measurement
A total of 3 mL of fasting venous blood was collected from
each participant into a potassium EDTA tube. Following
centrifugation, the plasma was transferred to an EppenTable. Descriptive table of study subjects.
Group

Number

Mean age

SD

Female

13

5.87

1.80

Male

67

6.60

2.80

Total

80

6.48

2.66

Female

19

6.70

2.00

Male

32

6.26

2.71

Total

51

6.43

2.45

Female

45

6.35

2.54

Male

41

5.81

2.52

Total

86

6.10

2.53

Autistic subjects

Siblings

Controls
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dorf tube and stored at –80 °C to be used for quantification of interleukin levels. Plasma interleukin levels were
measured using specific individual ELISA kits for each of
IL-6, IL-8, IL-9, IL-10, and TNF-α (RayBiotech Inc., Norcross, GA, USA) following the manufacturer’s recommendations. ELISA plates were read by a BioTek plate reader
(Winooski, VT, USA), and a graph of interleukin levels
was plotted using the reader’s software (Gen5). All samples
were measured three times each. Samples with spurious
measurements were removed from the study (six samples:
four from the ASD group and two from the control group).
Data were then averaged for each sample and run for statistical analysis.
2.3. Statistical analysis
For quantitative differences in plasma interleukin levels
between groups, statistical differences were investigated
using one-way analysis of variance (ANOVA) with
Bonferroni post hoc pairwise comparisons. When sex
was found as a confounding factor that could influence
interleukin differences between groups, linear regression
analysis was used to adjust for sex. All statistics were
evaluated using SPSS and P < 0.05 was considered to be
significant.
3. Results
The levels of IL-6, IL-8, IL-9, IL-10, and TNF-α were
measured in autistic children and compared to the levels
of their unaffected siblings and UHCs. We also tested
for differences between age and the interleukins using
Pearson’s correlation coefficient, yielding no significant
results.
One-way ANOVA for IL-6 revealed a statistical
difference in plasma levels between the groups [F(2,
215) = 18.25, P < 0.001]. Pairwise comparison revealed a
significantly higher level of IL-6 in both autistic subjects
(M = 143.51, SD = 118.28) and their siblings (M = 125.54,
SD = 80.89) compared to UHCs (M = 64.95, SD = 48.67)
(P < 0.001). No significant difference was detected between
the ASD group and siblings (P = 0.754), as shown in Figure
1A.
For IL-8 plasma levels, one-way ANOVA revealed
concentration differences between the groups [F(2,
215) = 14.22, P < 0.001]. Pairwise comparison revealed
significantly higher plasma levels in the autistic group (M
= 10.45, SD = 4.20) compared with both the siblings (M
= 7.27, SD = 3.78) (P < 0.001) and UHCs (M = 8.16, SD
= 2.85) (P < 0.001). However, pairwise comparisons did
not show any significant differences in IL-8 plasma levels
between the sibling and UHC groups (P = 0.488), as shown
in Figure 1B.
For TNF-α plasma levels, one-way ANOVA revealed
concentration differences between the groups [F (2,
215) = 26.54, P < 0.001]. Pairwise comparison revealed

significantly higher plasma levels in the autistic group
(M = 1611, SD = 585.4) compared with both siblings (M
= 1066, SD = 426.9) (P < 0.001) and UHCs (M = 1171,
SD = 377.8) (P < 0.001). However, pairwise comparison
did not show any significant difference in TNF-α plasma
levels between the sibling and UHC groups (P = 0.633), as
shown in Figure 1C.
No significant differences between the tested groups
were detected in IL-9 plasma levels [F(2, 215) = 1.94, P =
0.15] (P = 0.146) or IL-10 levels [F(2, 215) = 1.06, P = 0.35]
(P = 0.348), as shown in Figures 1D and 1E.
4. Discussion
In this study, the analysis of plasma cytokine levels
demonstrated differences between autistic Jordanian
children, their healthy unaffected siblings, and a control
group. Our data revealed significantly high levels of IL6, IL-8, and TNF-α compared to those of UHCs, but no
significant difference was observed for IL-9 and IL-10
levels. When cytokine levels were compared between
autistic children and their healthy siblings, significantly
higher levels of IL-8 and TNF-α were found in the autistic
group, while other cytokine analyses yielded no statistical
difference. On the other hand, plasma IL-6 levels were
higher in healthy siblings compared to UHCs. Given these
results, we suggest that the immune dysfunction and the
activation of immune responses involving the production
of IL-8 and TNF-α may possibly have a more significant
role in the pathophysiology of autism, while other
immunological factors such as IL-9 have a less direct role
in ASD development. Contrary to the literature, we believe
that IL-6 has less impact on ASD development, as healthy
unrelated siblings had high levels too. Immunological
factors that involve IL-6 activation may only have a
familial predisposition for ASD with minimal direct
pathophysiological involvement.
Our data have revealed elevated plasma levels of TNF-α
in patients with ASD compared with both UHCs and
siblings, suggesting a potential more direct role of TNF-α in
the pathophysiology of ASD. Tumor necrosis factor-α is a
proinflammatory cytokine that is a significant contributor
to homeostatic function and pathophysiological processes
in the central nervous system [17]. Pathological levels
of TNF-α potentiate the neurotoxic effect of glutamate,
leading to a synergistic induction of neuronal cell death
[18]. This affects the normal embryonic development of
the brain and also leads to the destruction of dendrites and
synaptic connections [19]. A study showed that there were
elevated levels of TNF-α in the amniotic fluid of mothers
carrying children with ASD compared to a control group
[20]. Another study demonstrated a correlation between
higher TNF-α levels and the severity of ASD symptoms
[21]. Likewise, Tsilioni et al. showed that children with ASD
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Figure 1. Mean serum concentrations of cytokines amongst groups. The bar charts show the differences in mean serum concentrations
of specific cytokines between ASD patients, siblings, and UHCs. A) Significantly higher IL-6 mean serum concentrations in ASD and
siblings compared to UHCs but no significant difference between ASD and siblings. B, C) Mean serum concentrations of IL-8 and
TNF-α, respectively, both showing significantly higher mean serum concentrations in ASD patients compared with UHCs and siblings
but no significant difference between siblings and UHCs. D, E) Mean serum concentrations of IL-9 and IL-10, respectively, showing no
significant difference in mean serum concentrations between any of the study groups. * P < 0.001.

had significantly higher serum TNF-α levels compared to
a control group. Reduction in serum TNF-α via a luteolincontaining diet was associated with improved behavioral
outcomes in children with ASD [22]. This emphasizes
the role of TNF-α in the pathophysiology of ASD. On the
other hand, only a few studies showed that there were no
significant differences or even lower levels of TNF-α in
children with ASD compared to controls [23,24].
Similar to TNF-α, IL-8 was elevated specifically in the
plasma of children with ASD. It is produced by phagocytic
cells exposed to certain stimuli also produced by TNF-α
[25], which might explain why IL-8 and TNF-α levels were
mutually elevated in ASD subjects. Also, higher levels
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of IL-8 were associated with more aberrant behaviors
in patients with ASD, including stereotypic behavior,
hyperactivity, less linguistic abilities, and cognitive ability
[26].
Another cytokine, IL-1β, is found to increase the
production of IL-17, which in part is a potent mediator of
IL-8 [27]. It is worth noting that both IL-1β and IL-17 are
commonly elevated in patients with ASD. Once activated,
IL-8 acts as a chemoattractant that attracts neutrophils to
areas of inflammation, causing the release of proteolytic
substances [28]. Therefore, elevated levels of IL-8 in both
brain and CSF samples of individuals with ASD support
a stronger role for IL-8 in the pathophysiology of ASD
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[29,30]. This study has revealed a significantly higher level
of IL-8 in autistic children compared to their siblings.
However, a similar study found no significant difference
between autistic children and their siblings [31]. This
inconsistency of results could be due to the different
genetic backgrounds of the samples in the two groups, or
the small sample size in the mentioned study.
As for IL-6, elevation of this cytokine has been a
repeated finding in autistic children. In comparison, we
found higher IL-6 levels in both children with ASD and
their siblings compared with UHCs. More importantly,
we found no significant plasma IL-6 level difference
in children with ASD compared to their siblings. This
finding is consistent with another study that found similar
results [31]. Although it was previously classified as a
proinflammatory cytokine and a major inducer of immune
and inflammatory response [32], recent studies have
shown an antiinflammatory role for IL-6 that prevents
increased tissue damage when transitioning from innate
to acquired immunity [33]. Furthermore, several studies
showed that IL-6 can also be produced by nonimmune
mediated cells such as mesenchymal cells, endothelial
cells, and fibroblasts, among others, in response to various
stimuli [34]. Some studies have revealed an increase in
IL-6 levels after exercise without muscle damage [35].
Even in brain tissue, IL-6 can be expressed by certain
astrocytoma and glioma lines under certain stimulation
[36]. These data might indicate that IL-6 can be elevated
in a wide range of conditions not limited to inflammation.
Hence, its direct role in the pathophysiology of autism
is questionable, which might also explain the absence of
significance noticed in our results between children with
ASD and their siblings. According to our results, since
IL-6 is found in the unaffected healthy siblings, we believe
its role in ASD pathophysiology might be overestimated.

However, further in-depth study of its exclusive role in
ASD development is necessary.
We found no significant difference in IL-9 and IL-10
plasma levels between autistic children, siblings, or the
control subjects. IL-9 also plays a vital role in autoimmune
activation of the CNS, yet our results are in concordance
with the literature. As for IL-10, Molloy et al., among
others, found results similar to our study where IL-10
levels in peripheral blood mononuclear cells did not differ
between ASD patients and control subjects despite the
elevation of levels of other cytokines [37]. These results
warrant more investigation of the possible roles of IL-9
and IL-10 in the pathophysiology of ASD.
This study has several limitations. Although our
sample size for children with ASD is larger than others
in the literature, we could not include all siblings and the
analysis would be stronger with a more comprehensive
siblings group. Also, all our ASD patients fell within one
subtype, and including other subtypes would help to clarify
things better. We hope to perform follow-up and check the
interleukin levels for the same sample population further
down the line, and we urge investigators to do prospective
studies as well.
In conclusion, our study was able to successfully
highlight IL-8 and TNF-α as biomarkers potentially
higher only in autistic children compared to other groups.
Although not dismissible, IL-6 is high in both children
with ASD and their healthy siblings in our sample,
questioning its importance as a biomarker. We hope our
results will help to better understand the disorder in terms
of its clinical and pathophysiological aspects.
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